RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy

NCT02452970 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Poor enrollment and adverse event experiences in the limited population

Conditions

Cholangiocarcinoma

Interventions

DRUG: RRx-001
DRUG: Gemcitabine and cisplatin

Sponsor

EpicentRx, Inc.